Dublin, Jan. 15, 2018 (GLOBE NEWSWIRE) -- The "Gastro Oesophageal Reflux Disease Forecast in 19 Major Markets 2017-2027" report has been added to ResearchAndMarkets.com's offering.

This report provides the current prevalent population for GORD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Norway, Sweden, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Gastro-oesophageal reflux disease (GORD) is a common disorder of the upper gastrointestinal tract. According to the most recent definition, it is a condition occurring when re?ux of gastric contents causes troublesome symptoms and/or complications. Based on endoscopy findings, the disease is broadly classified into two subtypes: demonstrating oesophageal mucosal damage (Erosive Reflux Disease, ERD) or no mucosal damage (Non-Erosive Reflux Disease, NERD). Injury to the oesophagus that may be associated with GORD is due to re?ux of gastric acid and pepsin, but also bile in the case of duodenogastric re?ux.

Providing a value-added level of insight, the two subtypes of the disease (ERD and NERD), as well as several of the main symptoms and co-morbidities of GORD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GORD include:

  • Globus
  • Non-cardiac chest pain
  • Asthma
  • Dysphagia
  • Dyspepsia
  • Chronic cough

Reasons to Buy:

  • Able to quantify patient populations in global GORD market to target the development of future products, pricing strategies and launch plans
  • Gain further insight into the prevalence of the subdivided types of GORD and identify patient segments with high potential
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries
  • Provide a level of understanding on the impact from specific co-morbid conditions on GORD prevalent population
  • Identify sub-populations within GORD which require treatment
  • Gain an understanding of the specific markets that have the largest number of GORD patients

Key Topics Covered:

  1. Introduction
  2. Cause of the Disease
  3. Risk Factors & Prevention
  4. Diagnosis of the Disease
  5. Variation by Geography/Ethnicity
  6. Disease Prognosis & Clinical Course
  7. Key Comorbid Conditions / Features Associated With the Disease
  8. Methodology for Quantification of Patient Numbers
  9. Top-Line Prevalence for Gastro-Oesophageal Reflux Disease
  10. Features of Gastro-Oesophageal Reflux Disease Patients
  11. Comorbid Conditions of Gord Patients
  12. Abbreviations Used in the Report
  13. Other Publications
  14. Online Patient-Based Databases
  15. Patient-Based Offering
  16. Online Pricing Data & Platforms
  17. References
  18. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/2prmj7/global_gastro?w=12



CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Gastrointestinal Drugs

Primary Logo